ECI Biotech Selected to Participate in the
Massachusetts Life Sciences Center Internship Challenge

Paid Summer Internships to Students Interested in Pursuing Careers in Life Sciences

June 14, 2011 - ECI Biotech (ECI), an innovative developer of the patented ExpressDetect® rapid infection sensors that will ultimately transform the way pathogens are detected in professional and OTC markets, is one of the select life sciences companies in the Commonwealth participating in the Massachusetts Life Sciences Center ("the Center") Internship Challenge Program. During the summer of 2011, ECI will provide practical experience to four full-time interns as part of its STEM workforce development program.

ECI has hired four interns from several MA universities and colleges to work at the company this summer. They are: Erik Herold, Boston University, Candidate for a B.S. in Mechanical Engineering; Daniel Marsden, Northeastern University, Candidate for a B.S. in Biochemistry with a minor in Psychology and Literature; Nhu Nguyen, Quinsigamond Community College and Biochemistry and Mathematics, Smith College; and Brenden Schauwecker, Quinsigamond Community College, Biotechnology Program. The purpose of the Internship Challenge is to provide interns with practical, "hands on" experience that will prepare them to step into the workforce ready to meet the job requirements of life sciences employers. The program, now in its third year, facilitates the placement of students and recent graduates who are considering career opportunities in the life sciences, in paid summer internships across the Commonwealth.

"ECI has hand-picked very talented individuals in biochemistry and engineering to work at our company this summer. The goal of hiring the interns is to provide them with relevant experience
and to further prepare them as viable candidates for full-time employment at ECI or within the industry," said Dr. Mitchell Sanders, CEO and Founder of ECI Biotech.

About ECI Biotech
Founded in 1998, ECI Biotech is a developer of affordable diagnostic sensors trademarked as ExpressDetect®. ECI has developed technology targeted at prognosing chronic and acute wound infections, which includes a dressing sensor and a rapid point of care diagnostic. ECI has established partnerships with leading medical device and consumer product companies to bring innovative discoveries to market on a global scale. ECI has a dominant patent portfolio that includes diagnostics, therapeutics, and advanced molecular technologies. If you're interested in partnering or would like to learn more about ECI Biotech, visit www.ecibiotech.com. Also follow us on Twitter, Facebook, LinkedIn & YouTube.

^top